Clinical Trial
doi: 10.1086/317479.
Reactogenicity and immunogenicity of a Lyme disease vaccine in children 2-5 years old
Affiliations
- PMID: 11096024
- DOI: 10.1086/317479
Item in Clipboard
Clinical Trial
Reactogenicity and immunogenicity of a Lyme disease vaccine in children 2-5 years old
Clin Infect Dis.
2000 Dec.
Abstract
Two doses of a recombinant Lyme disease vaccine (15 and 30 microg) were administered to children 2-5 years old (0-1-month schedule) and were well tolerated. Both doses were highly immunogenic with geometric mean titers 1 month after vaccination of 4366 and 9877 ELISA units (EU)/mL, respectively. Nearly all subjects had antibody levels of > or = 1400 EU/mL, suggesting protective tick titre for one tick season.
Similar articles
-
Safety and immunogenicity profile of a recombinant outer-surface protein A Lyme disease vaccine: clinical trial of a 3-dose schedule at 0, 1, and 2 months.Clin Ther. 2000 Mar;22(3):315-25. doi: 10.1016/S0149-2918(00)80035-1. Clin Ther. 2000. PMID: 10963286 Clinical Trial.
-
Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A lyme disease vaccination.Clin Infect Dis. 2000 Jul;31(1):42-7. doi: 10.1086/313920. Epub 2000 Jul 17. Clin Infect Dis. 2000. PMID: 10913394
-
Safety and immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against lyme disease in healthy children and adolescents: a randomized controlled trial.Pediatrics. 2001 Jul;108(1):123-8. doi: 10.1542/peds.108.1.123. Pediatrics. 2001. PMID: 11433064 Clinical Trial.
-
A recombinant vaccine for Lyme disease.Behring Inst Mitt. 1994 Dec;(95):106-8. Behring Inst Mitt. 1994. PMID: 7755503 Review.
-
Approaches toward the directed design of a vaccine against Borrelia burgdorferi.J Infect Dis. 2002 Feb 15;185 Suppl 1:S46-51. doi: 10.1086/338463. J Infect Dis. 2002. PMID: 11865439 Review.
Cited by
-
Toll-Like Receptor Ligand Based Adjuvant, PorB, Increases Antigen Deposition on Germinal Center Follicular Dendritic Cells While Enhancing the Follicular Dendritic Cells Network.Front Immunol. 2020 Jun 19;11:1254. doi: 10.3389/fimmu.2020.01254. eCollection 2020. Front Immunol. 2020. PMID: 32636846 Free PMC article.
-
CD169+ Subcapsular Macrophage Role in Antigen Adjuvant Activity.Front Immunol. 2021 Mar 18;12:624197. doi: 10.3389/fimmu.2021.624197. eCollection 2021. Front Immunol. 2021. PMID: 33815376 Free PMC article.
-
TLR-based immune adjuvants.Vaccine. 2011 Apr 12;29(17):3341-55. doi: 10.1016/j.vaccine.2010.08.002. Epub 2010 Aug 14. Vaccine. 2011. PMID: 20713100 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
